Literature DB >> 24526096

Treatment of DEAP-HUS--seeking the best strategy.

Christoph Licht1, Damien Noone.   

Abstract

Mesh：

Substances：

Year:  2014        PMID： 24526096     DOI： 10.1007/s00467-014-2767-x

Source DB:  PubMed          Journal:  Pediatr Nephrol        ISSN： 0931-041X            Impact factor:   3.714


× No keyword cloud information.
  3 in total

1.  Therapy for patients with antibodies to complement factor H associated HUS.

Authors:  Arvind Bagga; Aditi Sinha; Marie-Agnes Dragon-Durey
Journal:  Pediatr Nephrol       Date:  2014-01-22       Impact factor: 3.714

2.  Prompt plasma exchanges and immunosuppressive treatment improves the outcomes of anti-factor H autoantibody-associated hemolytic uremic syndrome in children.

Authors:  Aditi Sinha; Ashima Gulati; Savita Saini; Caroline Blanc; Aarti Gupta; Bahadur Singh Gurjar; Himanshi Saini; Shambhuprasad T Kotresh; Uma Ali; Divya Bhatia; Alpana Ohri; Manish Kumar; Indira Agarwal; Sanjeev Gulati; Kanav Anand; M Vijayakumar; Rajiv Sinha; Sidharth Sethi; Maud Salmona; Anna George; Vineeta Bal; Geetika Singh; Amit K Dinda; Pankaj Hari; Satyajit Rath; Marie-Agnes Dragon-Durey; Arvind Bagga
Journal:  Kidney Int       Date:  2013-10-02       Impact factor: 10.612

3.  Successful treatment of DEAP-HUS with eculizumab.

Authors:  Damien Noone; Aoife Waters; Fred G Pluthero; Denis F Geary; Michael Kirschfink; Peter F Zipfel; Christoph Licht
Journal:  Pediatr Nephrol       Date:  2013-11-20       Impact factor: 3.714
  3 in total
  1 in total

Review 1.  Successful discontinuation of eculizumab under immunosuppressive therapy in DEAP-HUS.

Authors:  Agnes Hackl; Rasmus Ehren; Michael Kirschfink; Peter F Zipfel; Bodo B Beck; Lutz T Weber; Sandra Habbig
Journal:  Pediatr Nephrol       Date:  2017-02-20       Impact factor: 3.714
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.